Old Web
English
Sign In
Acemap
>
authorDetail
>
Hangzhong Li
Hangzhong Li
Peking Union Medical College Hospital
Clinical endpoint
Pathology
Sunitinib
Renal cell carcinoma
Medicine
2
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.
2016
Journal of Clinical Oncology
Aiping Zhou
Yuxian Bai
Yan Song
Hangzhong Li
Xiaodong Xie
Xiubao Ren
Dingwei Ye
Jiyan Liu
Hong Luo
Xianzhong Bai
Shukui Qin
Cheng Fu
Jinwan Wang
Jianhui Ma
Show All
Source
Cite
Save
Citations (6)
Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.
2016
Journal of Clinical Oncology
Aiping Zhou
Jianhui Ma
Yuxian Bai
Yan Song
Hangzhong Li
Xiaodong Xie
Xiubao Ren
Dingwei Ye
Jiyan Liu
Hong Luo
Xianzhong Bai
Shukui Qin
Cheng Fu
Jinwan Wang
Show All
Source
Cite
Save
Citations (6)
1